JOIN OUR
CLINICAL TRIAL
TearSolutions has developed a proprietary
synthetic fragment of lacritin, Lacripep™
Clinical Study in St. Louis, MO
Are you interested in participating in a clinical trial for Lacripep, a topical ophthalmic therapy designed to treat Primary Sjogren’s Syndrome, in St. Louis?
Primary Sjogren’s Syndrome, an autoimmune disease which can cause a severe form of Dry Eye Disease (DED), can be caused by both genetic and environmental factors, and is particularly prominent in women. Almost 70 million Americans suffer from some form of DED, which is often due to tear film disruption. The tear film of the human eye is critical for the survival of corneal epithelial cells and sensory neurons.
Treating DED is a process that is often complicated and frustrating since it is challenging to effectively treat patients without causing uncomfortable side effects. At TearSolutions, we’re committed to developing innovative treatments for Dry Eye that have a best-in-class comfort profile. After decades of scientific study, Dr. Gordon Laurie, our co-founder and Chief Scientific Officer, has identified the root cause of all forms of DED as a deficiency of lacritin, a naturally-occurring protein which helps the eye produce basal tears and repair damaged cells. Dr. Laurie’s research has enabled ophthalmologists and optometrists to quickly, safely and comfortably restore the ocular surface of patients suffering from DED.
Lacripep
TearSolutions has developed Lacripep, the ultimate solution for DED, which is the first product derived from lacritin, representing a new class of naturally-occurring restorative peptides. Lacripep is a topical ophthalmic drop which maintains the biological activity of lacritin in a peptide. Unlike existing treatments which merely mask the symptoms of DED, Lacripep is designed to restore comprehensive cellular health to the cornea and to restore basal tearing. The science behind Lacripep has been in development for 30 years and has been independently validated in numerous peer-reviewed publications.
Preclinical studies demonstrated that when Lacripep was used on animals, it restored basal tearing and healed the cornea without causing any irritation. In our first Phase I/II human trials, TearSolutions discovered that Lacripep is highly effective in reducing symptoms and restoring corneal health in a majority of people with Primary Sjogren’s Syndrome in as little as two weeks. By contrast, current treatments for DED can take months to provide relief and are often uncomfortable to use. Now, TearSolutions is preparing our next clinical study for Lacripep in St. Louis.
If you’ve been suffering from the effects of DED associated with Primary Sjogren’s Syndrome, Lacripep may be the solution you’ve been waiting for. Lacripep is designed to be a quick, safe and simple solution to the relentless irritation caused by DED. Contact TearSolutions today to learn more about our Lacripep clinical trial in St. Louis.